Rhumbline Advisers Kal Vista Pharmaceuticals, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q4 2024

A detailed history of Rhumbline Advisers transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 51,156 shares of KALV stock, worth $499,282. This represents 0.0% of its overall portfolio holdings.

Number of Shares

51,156

Previous 50,279 1.74%

Holding current value

$499,282

Previous $582,000 25.6%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 30, 2025	BUY	$8.09 - $12.5 $7,094 - $10,962	877 Added 1.74%	51,156 $433,000
Q3 2024 Nov 12, 2024	SELL	$9.46 - $15.39 $27,897 - $45,385	-2,949 Reduced 5.54%	50,279 $582,000
Q2 2024 Aug 01, 2024	BUY	$10.35 - $12.49 $61,147 - $73,790	5,908 Added 12.49%	53,228 $627,000
Q1 2024 May 09, 2024	BUY	$11.07 - $16.04 $21,686 - $31,422	1,959 Added 4.32%	47,320 $561,000
Q4 2023 Feb 08, 2024	BUY	$7.58 - $12.25 $26,272 - $42,458	3,466 Added 8.27%	45,361 $555,000
Q3 2023 Nov 09, 2023	BUY	$8.95 - $11.35 $1,467 - $1,861	164 Added 0.39%	41,895 $403,000
Q2 2023 Aug 08, 2023	BUY	$7.73 - $10.57 $22,486 - $30,748	2,909 Added 7.49%	41,731 $375,000
Q1 2023 May 11, 2023	BUY	$6.3 - $8.39 $7,793 - $10,378	1,237 Added 3.29%	38,822 $305,000
Q4 2022 Feb 14, 2023	BUY	$4.2 - $14.24 $302 - $1,025	72 Added 0.19%	37,585 $254,000
Q3 2022 Nov 10, 2022	BUY	$9.85 - $16.83 $28,013 - $47,864	2,844 Added 8.2%	37,513 $544,000
Q2 2022 Aug 11, 2022	BUY	$8.16 - $15.1 $102,155 - $189,036	12,519 Added 56.52%	34,669 $341,000
Q1 2022 May 12, 2022	BUY	$11.2 - $16.97 $34,720 - $52,607	3,100 Added 16.27%	22,150 $326,000
Q4 2021 Feb 10, 2022	SELL	$12.36 - $18.28 $135 - $201	-11 Reduced 0.06%	19,050 $252,000
Q3 2021 Nov 12, 2021	BUY	$17.11 - $24.49 $15,347 - $21,967	897 Added 4.94%	19,061 $333,000
Q2 2021 Aug 05, 2021	SELL	$23.12 - $29.91 $115,900 - $149,938	-5,013 Reduced 21.63%	18,164 $435,000
Q1 2021 May 06, 2021	BUY	$14.69 - $42.57 $61,521 - $178,283	4,188 Added 22.05%	23,177 $595,000
Q4 2020 Feb 10, 2021	BUY	$12.88 - $19.47 $41,679 - $63,004	3,236 Added 20.54%	18,989 $361,000
Q3 2020 Nov 12, 2020	SELL	$9.83 - $13.99 $18,647 - $26,539	-1,897 Reduced 10.75%	15,753 $198,000
Q2 2020 Aug 13, 2020	BUY	$6.75 - $12.89 $46,730 - $89,237	6,923 Added 64.54%	17,650 $214,000
Q1 2020 May 06, 2020	SELL	$5.8 - $18.56 $870 - $2,784	-150 Reduced 1.38%	10,727 $82,000
Q4 2019 Feb 05, 2020	BUY	$10.31 - $17.81 $2,453 - $4,238	238 Added 2.24%	10,877 $194,000
Q3 2019 Oct 23, 2019	SELL	$11.6 - $21.67 $928 - $1,733	-80 Reduced 0.75%	10,639 $123,000
Q2 2019 Aug 14, 2019	BUY	$18.44 - $30.89 $197,658 - $331,109	10,719 New	10,719 $237,000

Others Institutions Holding KALV

# of Institutions

135

Shares Held

52M

Call Options Held

551K

Put Options Held

98K

View Full List

About KalVista Pharmaceuticals, Inc.

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $240M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

More about KALV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Kal Vista Pharmaceuticals, Inc. Transaction History